Literature DB >> 24807846

Sacroiliac joint involvement in systemic sclerosis.

Didem Arslan Tas1, Fatih Yıldız, Hakan Sakallı, Bayram Kelle, Tuğsan Ballı, Eren Erken.   

Abstract

AIM: One of the major problems for systemic sclerosis (SSc) patients is suggested to be articular involvement. Mostly involved joints in SSc were reported as wrist, carpometacarpal-interphalangeal, foot, knee, hip and shoulder; however, there has been little knowledge on the sacroiliac joint. Our aim was to evaluate sacroiliac joint involvement in SSc.
METHODS: Fifty-seven SSc patients, 54 rheumatoid arthritis patients and 64 healthy subjects were included. Anteroposterior pelvic radiographs were obtained and graded twice by three blinded rheumatologists. One competent radiologist has re-evaluated the X-ray results. The ASAS (Assessment of Spondylo Arthritis International Society) scoring method was applied for grading sacroiliac involvement. Inflammatory back pain was also evaluated. Other clinical and laboratory data were collected as proposed by the European Study Group.
RESULTS: In the SSc group sacroiliitis was found in 13 patients (23%) and was significantly different from RA patients (two patients, 4%), P = 0.003; and the healthy control group (one participant, 2%), P < 0.001. The frequency of inflammatory back pain in SSc patients with sacroiliitis (8/13 patients, 62%) was significantly higher in SSc patients without sacroiliitis (4/44 patients, 9%), P < 0.001. The SSc patients with sacroiliitis and with inflammatory back pain (8/57 patients, 14%) were regarded as axial spondyloarthritis overlap. Male gender, diffuse subtype, inflammatory back pain and high C-reactive protein levels (odds ratio: 1.069, 1.059, 1.059 and 3.698, respectively) were found to be the significant risk factors for sacroiliitis.
CONCLUSION: We suggest that, sacroiliitis may be a concern to be considered in SSc practice.
© 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  sacroiliitis; spondyloarthropathy; systemic sclerosis

Mesh:

Substances:

Year:  2014        PMID: 24807846     DOI: 10.1111/1756-185X.12379

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  2 in total

Review 1.  Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review.

Authors:  Avgoustina Kyriakou; Konstantinos Parperis; Elena Nikiphorou; Savvas Psarelis
Journal:  Rheumatol Int       Date:  2021-01-12       Impact factor: 2.631

2.  Sacroiliitis Detected by Magnetic Resonance Imaging in Patients With Systemic Sclerosis.

Authors:  Didem Arslan; İpek Türk; Erkan Kozanoğlu; Özlem Kudaş; Bayram Kelle; Hakan Sakalli
Journal:  Arch Rheumatol       Date:  2020-01-03       Impact factor: 1.472

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.